Prana Alzheimer's Study Fails

Prana Biotechnology's (PRAN) phase II study of PBT2 in Alzheimer's disease failed, the company announced Monday morning.

Shares of Prana are down 75% to $2.51 in pre-market trading. 

The experimental PBT2 did not meet the study's primary endpoint of a statistically significant reduction in levels of beta amyloid plaque in the brains of patients with prodromal or mild Alzheimer's, as measured using PET imaging. 

PBT2 also failed to demonstrate an improvement in brain metabolic activity, cognition or function compared to placebo. 

A previous phase II study of PBT2 in Huntington's disease also failed, although Prana insists the study was positive and plans to conduct a confirmatory study in the future. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes